Materias dentro de su búsqueda.
Materias dentro de su búsqueda.
Leyes y legislación
22
Patentes de invención
22
Propiedad industrial
15
Patentes
11
Derechos de autor
8
Marcas de fábrica
5
Historia
4
México
3
Transferencia de tecnología
3
Aspectos ambientales
2
Biotecnología
2
Biotecnología agrícola
2
Ciencia
2
Criptografía
2
Genes
2
Ingeniería genética
2
Literatura española
2
Marcas
2
Monopolios
2
PATENTES
2
PATENTS
2
Patents
2
Propiedad intelectual
2
Universidades
2
ACADEMIC PRODUCTION
1
ACADEMIC WOMEN
1
ANÁLISIS BIBLIOMÉTRICO
1
Acuerdos (Derecho)
1
Administración pública
1
Agricultura
1
-
8881por Mehrvar, Cina, Deignan, Emily, Hurtig, Mark, Cohen, Gideon, Zalzal, Paul, Safir, Oleg, Alhalawani, Adel, Papini, Marcello, Towler, Mark R.“…An emerging treatment option has been to augment the wires with an adhesive. A patented ionomeric glass (mole fraction: SiO(2):0.48, ZnO:0.36, CaO:0.12, SrO:0.04) has been used to formulate GPC+, a glass polyalkenoate cement (GPC), by mixing it with poly(acrylic) acid (PAA) and de-ionized water. …”
Publicado 2021
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
8882por Freire Boullosa, Laurie, Van Loenhout, Jinthe, Flieswasser, Tal, De Waele, Jorrit, Hermans, Christophe, Lambrechts, Hilde, Cuypers, Bart, Laukens, Kris, Bartholomeus, Esther, Siozopoulou, Vasiliki, De Vos, Winnok H., Peeters, Marc, Smits, Evelien L.J., Deben, Christophe“…Our data provides novel insights on AF as a potent, clinically available, off-patent cancer drug by targeting mutant p53 cancer cells through distinct cell death mechanisms (apoptosis and ferroptosis). …”
Publicado 2021
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
8883por Raimondo, Stefania, Nikolic, Dragana, Conigliaro, Alice, Giavaresi, Gianluca, Lo Sasso, Bruna, Giglio, Rosaria Vincenza, Chianetta, Roberta, Manno, Mauro, Raccosta, Samuele, Corleone, Valeria, Ferrante, Giovanni, Citarrella, Roberto, Rizzo, Manfredi, De Leo, Giacomo, Ciaccio, Marcello, Montalto, Giuseppe, Alessandro, Riccardo“…The present study aimed to assess the safety of the new patented plant-based product citraVes™, containing extracellular vesicles (EVs) from Citrus limon (L.) …”
Publicado 2021
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
8884“…Overall mean follow-up was 140.84 ± 160.41 days (median 70, range 4–590). All stents remained patent with no evidence of recurrent GOO symptoms. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
8885por Heinicke, Thomas, Krahl, Rainer, Kahl, Christoph, Cross, Michael, Scholl, Sebastian, Wolf, Hans-Heinrich, Hähling, Detlev, Hegenbart, Ute, Peter, Norma, Schulze, Antje, Florschütz, Axel, Schmidt, Volker, Reifenrath, Kolja, Zojer, Niklas, Junghanss, Christian, Sayer, Herbert G., Maschmeyer, Georg, Späth, Christian, Hochhaus, Andreas, Fischer, Thomas, Al-Ali, Haifa Kathrin, Niederwieser, Dietger“…Lower relapse incidence was observed in patents with HCT, long CR1 duration, and female gender. …”
Publicado 2021
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
8886“…In this context, regulators’ disregard of synergism contrasted irreconcilably with biocide manufacturers’ understanding that synergism enhanced lethality and patentability. In the end, an effective national response to mixture toxicity, cumulative risk, and environmental injustice did not emerge. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
8887por Deleuze, Stefan, Brotcorne, Fany, Polet, Roland, Soma, Gede, Rigaux, Goulven, Giraud, Gwennan, Cloutier, Fanny, Poncin, Pascal, Wandia, Nengah, Huynen, Marie-Claude“…A laparoscopic post-operative evaluation conducted on two patients during the following campaign confirmed that the oviducts were definitely disrupted and no longer patent. Moreover, no new pregnancies in sterilized females were recorded during the 3-year observation period. …”
Publicado 2021
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
8888“…IP rights (particularly patents) are integral to the translation of research into clinically relevant outcomes and, therefore, are key features in the business models of many biobanks. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
8889por Negalur, Natasha Vijay, Ekbote, Gayatri G., Raval, Dhiren N., Tanna, Dhaval V., Kazi, Wasim S., Bindroo, Muzaffar A., Yadavalli, Durgarao J., Gupta, Rajiva“…METHODS AND MATERIALS: Consecutive AIM patents were divided into groups as dermatomyositis (DM), polymyositis (PM), CTD-associated myositis (CTD-M), cancer-associated myositis (CAM) and juvenile myositis (JM). …”
Publicado 2021
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
8890por Guerrieri, Alessandra, Floková, Kristýna, Vlaar, Lieke E., Schilder, Mario L., Kramer, Gertjan, Chojnacka, Aleksandra, van Dijk, Yannick R., Bouwmeester, Harro J., Dong, Lemeng“…Earlier reports (Mulder et al. in Hatching agent for the potato cyst nematode, Patent application No. PCT/NL92/00126, 1996; Schenk et al. in Croat Chem Acta 72:593–606, 1999) showed that solanoeclepin A (SolA), a triterpenoid metabolite that was isolated from the root exudate of potato, induces the hatching of PCN. …”
Publicado 2021
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
8891“…METHODS: Trio-whole-exome sequencing was applied to identify pathogenic gene mutations in seven patents with short stature, multiple malformations, and/or intellectual disability. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
8892por McAllister, James P., Talcott, Michael R., Isaacs, Albert M., Zwick, Sarah H., Garcia-Bonilla, Maria, Castaneyra-Ruiz, Leandro, Hartman, Alexis L., Dilger, Ryan N., Fleming, Stephen A., Golden, Rebecca K., Morales, Diego M., Harris, Carolyn A., Limbrick, David D.“…Kaolin deposits formed a solid cast in the basal cisterns but the cisterna magna was patent. In 17 untreated hydrocephalic animals. Mean total ventricular volume was 8898 ± 5917 SD mm(3) at 11–43 days of age, which was significantly larger than the baseline values of 2251 ± 194 SD mm(3) for 6 sham controls aged 45–55 days, (p < 0.001). …”
Publicado 2021
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
8893por Xu, Qianhui, Wang, Qian, Han, Jing, Mao, Fengju, Zeng, Silin, Chen, Siyan, Zhao, Chenyong, Gu, Mei, Li, Zaiwang, Fu, Xuejun, Luo, Xiaoguang, Huang, Ying“…All patients received first-line therapy (glucocorticoids, intravenous immunoglobulin, or plasmapheresis alone or combined), whereas two patients (6.5%) received rituximab, a second-line agent, as well. Seven patents required mechanical ventilation. Results of univariate logistic regression analysis revealed that body temperature ≥38°C [odds ratio (OR) = 18, 95% confidence interval (CI): 1.79–181.31, P < 0.05] and central hypoventilation at admission (OR = 57.50, 95% CI: 4.32–764.89, P < 0.05) were the risk factors for mechanical ventilation. …”
Publicado 2021
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
8894por Kiparoglou, Vasiliki, Brown, Laurence A., McShane, Helen, Channon, Keith M., Shah, Syed Ghulam Sarwar“…Further research involving continued uptake of unique persistent identifiers and the tracking of other research outputs such as clinical innovations and patents would allow a more detailed understanding of large research enterprises such as NIHR BRCs in the UK. …”
Publicado 2021
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
8895por Zhang, Jiawei, Zhang, Zhe, Fu, Lingyu, Wang, Lei, Yang, Yu, Wang, Hao, Zhou, Baosen, Wang, Wei, Zhang, Jian, Xin, Shijie“…The false lumen (FL) status was evaluated and classified as partially thrombosed, patent, or completely thrombosed. Results: The OSA prevalence in TBAD patients was 64.3%, and image differences related to LAEs between TBAD patients with and without OSA included the maximum aortic diameter at onset (37.3 ± 3.9 vs. 40.3 ± 4.5 mm, p < 0.001), the FL diameter of the proximal descending thoracic aorta (16.0 ± 6.8 vs. 20.3 ± 4.7 mm, p < 0.001), and the proportion of the FL that was partially thrombosed (39.2 vs. 64.1%, p = 0.004). …”
Publicado 2021
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
8896“…RESULTS: In the experimental group, the BPD incidence [−0.71, 95% confidential interval (CI): −0.34 to −0.00; Z=1.98; P=0.05], 28-day oxygen uptake rate (0.81, 95% CI: 0.38–1.730; Z=0.53; P=0.59), 36-week survival rate (1.08, 95% CI: 0.80–1.46; Z=0.49; P=0.62), incidence of patent ductus arteriosus (0.77, 95% CI: 0.27–2.21; Z=0.48; P=0.63), days of mechanical ventilation (0.02, 95% CI: −1.46–1.49; Z=0.02; P=0.98), and 28-day ventilator use (0.77, 95% CI: 0.31–1.92; Z=0.55; P=0.58) were lower than those in the control group, especially the incidence of BPD. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
8897por Mohammadi, Hanieh, Mohammadpour Ahranjani, Behzad, Aghaei Moghadam, Ehsan, Kompani, Farzad, Mirbeyk, Mona, Rezaei, Nima“…RESULTS: A total of 191 (76.7%) patients with Ventricular Septal Defects (VSD), 37 (14.85%) patients with Atrial Septal Defects (ASD), and 20 (8.11%) patients with Patent Ductus Arteriosus (PDA) were enrolled in this study. …”
Publicado 2022
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
8898por Chlupac, Jaroslav, Matejka, Roman, Konarik, Miroslav, Novotny, Robert, Simunkova, Zuzana, Mrazova, Iveta, Fabian, Ondrej, Zapletal, Milan, Pulda, Zdenek, Lipensky, Jan Falk, Stepanovska, Jana, Hanzalek, Karel, Broz, Antonin, Novak, Tomas, Lodererova, Alena, Voska, Ludek, Adla, Theodor, Fronek, Jiri, Rozkot, Miroslav, Forostyak, Serhiy, Kneppo, Peter, Bacakova, Lucie, Pirk, Jan“…Results: All grafts were well-integrated and patent with no signs of thrombosis, stenosis, or aneurysm. …”
Publicado 2022
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
8899por Ning, Kang, Wu, Zeshen, Zou, Xiangpeng, Liu, Huiming, Wu, Yi, Xiong, Longbin, Yu, Chunping, Guo, Shengjie, Han, Hui, Zhou, Fangjian, Dong, Pei, Zhang, Zhiling“…Log-rank analysis identified proteinuria deterioration and eGFR decline were both significantly associated with patent’s survival (P<0.001). CONCLUSIONS: Targeted therapy was associated with an increase in proteinuria level and a decrease in eGFR in patients with mRCC. …”
Publicado 2022
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
8900por Zhang, Xing, Guo, Qiujun, Li, Conghuang, Liu, Rui, Xu, Tao, Jin, Zhichao, Xi, Yupeng, Qin, Yinggang, Li, Weidong, Chen, Shuntai, Xu, Ling, Lin, Lizhu, Shao, Kang, Wang, Shenyu, Xie, Ying, Sun, Hong, Li, Ping, Chu, Xiangyang, Chai, Kequn, Shu, Qijin, Liu, Yanqing, Zhang, Yue, Hu, Jiaqi, Shi, Bolun, Zhang, Xiwen, Zhang, Zhenhua, Jiang, Juling, He, Shulin, He, Jie, Sun, Mingxi, Zhang, Ying, Zhang, Meiying, Zheng, Honggang, Hou, Wei, Hua, Baojin“…Patients who received Chinese herbal decoction and (or) oral Chinese patent medicine for a cumulative period of not less than 6 months were defined as TCM group, otherwise they were considered as control group. …”
Publicado 2022
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto